A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma
Status:
Not yet recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study to find out whether the combination of lenvatinib and pembrolizumab
is an effective treatment for advanced uterine carcinosarcoma. The researchers will also do
tests to find out whether biomarkers in the blood can predict the cancer's response to the
study treatment. A biomarker is a biological molecule found in blood, other body fluids, or
tissues that is a sign of a normal or abnormal process, or of a condition or disease. A
biomarker may be used to see how well the body responds to a treatment for a disease or
condition